On account of its histamine releasing and ganglion blocking properties tubocurarine is known to have significant haemodynamic effects. Methylation of the compound produces metocurine and should decrease both histamine release and ganglionic blockade. The haemodynamic effects of these two compounds were compared in 10 mongrel dogs anaesthetized with chloralose and morphine. Haemodynamic measurements were made 2 min before and 2, 5, 10 and 20 min after administration of the drugs. Each animal received three doses of each drug with a 2-h rest period between doses: tubocurarine 0.35 (muscle twitch ED 95 ), 0.7 and l.-lmgkg-1 and metocurine 0.2 (2xED, s ), 0.4 and 0.8 mg kg"" 1 . All doses of tubocurarine produced an increase in heart rate (212, 197 and 212% of control respectively). The mean arterial pressure decreased significantly with 0.7 mg kg" 1 (48% of control; / ) <0.05). Metocurine produced no significant haemodynamic effects except for the largest dose (8 x ED 95 ). The data suggest that the haemodynamic margin of safety with metocurine in the dog is eight times that of tubocurarine.
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In recent years, there has been a renewed interest in the use of dimethyltubocurarine (metocurine) in clinical practice (Savarese, Ali and Antonio, 1977) . Structure-activity relationships would predict that the bisquaternary metocurine should produce less histamine release, less profound ganglion blockade and thus lesser haemodynamic side-effects than its monoquaternary analogue tubocurarine. Previous studies have demonstrated that metocurine inhibits neither vagal nor sympathetic activity in cats or monkeys (Hughes and Chappie, 1976a, b) and produces less histamine release (McCullough et al., 1972; Savarese, 1979) .
We have compared the haemodynamic effects of metocurine and tubocurarine in dogs.
METHODS
Ten mongrel dogs weighing 17-25 kg were anaesthetized with alpha chloralose 100 mg kg" 1 and morphine 1 mg kg" 1 i.v. Arterial pressure was measured in the abdominal aorta via a catheter introduced through the left femoral artery. Central venous, pulmonary artery and pulmonary capillary wedge pressures were recorded via catheters introduced to the right external jugular vein. Heart rate was measured with a tachograph triggered by the arterial pulse wave. Cardiac output was measured by a dye dilution technique using indocyanine green dye and a Beckman recording densitometer. Neuromuscular blockade was measured by the twitch response of the right tibialis anterior muscle stimulated through the peroneal nerve with supramaximal square wave stimuli 0.2 ms in duration at 0.15 Hz. Lung ventilation was controlled to maintain the end-tidal carbon dioxide at 3.5-4.5% recorded by a Beckman LB-1 medical gas analyser.
Following the insertion of the catheters and establishment of a steady state, control measurements were obtained. The animals were then divided arbitrarily into two groups. In group I tubocurarine was given i.v. at three doses-0.35, 0.7 and 1.4 mg kg" 1 with a 2-h rest period between each dose. Group II received metocurine at doses of 0.2, 0.4 and 0.8 mg kg" 1 with the same rest period. Following the administration of the drug, haemodynamic measurements were made at 2, 5, 10 and 20 min for each dose in each group.
RESULTS
Haemodynamic data are in tables I and II for group I (tubocurarine) and group II (metocurine) at 2 min. Following the administration of tubocurarine 0.35 mg kg"
1 there was an increase of 212% from control in heart rate (/ > <0.05). Central venous pressure decreased to 28% of control (P< 0.05) and mean arterial pressure to 70% of control (n.s.). Similar changes occurred with 0.7 and l^mgkg" 1 . There were no significant changes in cardiac output.
In group II, there were no significant changes throughout the study period at doses of 0.2 mg kg" 1 . With 0.4 mg kg" 1 there was a significant increase in heart rate and decrease in systemic vascular resistance. Only at 0.8 mg kg" 1 were changes, comparable with those obtained with low-dose tubocurarine, noted.
DISCUSSION
The chloralose-morphine anaesthetic technique was chosen to produce a preparation with high autonomic tone and slow baseline heart rate, a vagotonic preparation analogous to the clinical findings in adult man.
The initial dose of tubocurarine (0.35 mg kg" 1 ) was chosen to represent approximately ED 95 for neuromuscular blockade in the dog. Subsequent doses were then two and four times ED 85 respectively.
The initial dose of metocurine (0.2 mg kg" 1 ) represents twice ED 95 for this drug in the dog (Mogey and Trevan, 1950; Donlon, Ah and Savarese, 1974) with subsequent doses-thus representing four and eight times ED 95 .
It was apparent that the initial dose of tubocurarine (ED 95 ) and all subsequent doses produced profound haemodynamic changes within 2 min of administration. Such responses are well documented clinically. It was apparent also that no significant haemodynamic change occurred with metocurine at two or four times ED 95 . Only at eight times the neuromuscular ED 95 did metocurine produce changes similar to those noted for tubocurarine at ED 95 . These data demonstrate that the safety margin for haemodynamic change after metocurine in the dog is therefore eight times greater than that of tubocurarine.
Although metocurine has been available since its synthesis by King in 1935, it has not been popular in clinical use despite early studies suggesting less histamine release (Wilson, Gordon and Raffan, 1950) and little effect on arterial pressure (Stoelting, Graf and Vieira, 1948) . More recent studies have confirmed the absence of significant autonomic effects both in animals (Hughes and Chappie, 1976a; Savarese, 1979) and man (Savarese, Ali and Antonio, 1977; Zaiden et al., 1977) . The unpopularity may be in some part the result of difficulty in synthesizing the drug and maintaining batch-to-batch potency (Mogey and Trevan, 1950) . This is no longer the case (Savarese, Ali and Antonio, 1977) .
While the neuromuscular blocking action of metocurine does not differ substantially from those of other non-depolarizing agents, its cardiovascular effects are different and this may offer a distinct advantage. Metocurine does not block the cardiac muscarinic receptors (Hughes and Chappie, 1976b; Savarese, 1979 ) and thus does not produce a tachycardia (Stoelting, 1974) unless histamine release occurs. This appears to require significantly greater doses than with tubocurarine. This, and its weaker ganglionic-blocking action, reduces the risk of hypotension.
The wide margin of safety for haemodynamic effects between metocurine and tubocurarine shown in this study suggests that the former may be the relaxant of choice for patients with cardiac disease. Its weak ganglion-blocking and histamine releasing properties and its lack of vagolytic (cardiac muscarinic) blocking action may render it appropriate for patients with coronary artery disease where tachycardia and hypotension may result in myocardial ischaemia.
RESUME
On sait que la tubocurarine produit des effets h£mo-dynamiques significatifs en raison des proprietes qu'elle possede et qui sont a l'origine du degagement d'histamine et du blocage des ganglions. Le traitement au m£thyle de ce compose produit de la metocurine et celle-ci devrait permettre de diminuer aussi bien le degagement d'histamine que le blocage des ganglions. On a procede a une comparaison des effets hemodynamiques de ces deux composes sur 10 chiens batards anesthesias a l'aide de chloralose et de morphine. Les mesures hemodynamiques ont ete prises 2 min avant et 2, 5, 10 et 20 min apres l'administration des medicaments. Chaque animal a recu trois doses de chacun des medicaments, avec une periode de repos de 2 h entre les doses: rubocurarine 0,35 (crispation du muscle ED 85 ), 0,7 et 1,4 mg kg-1 et metocurine 0,2 (2 x ED 85 ), 0,4 et 0,8 mg kg-1 . Toutes les doses de tubocurarine ont produit une augmentation de la frequence cardiaque (respectivement 212, 197, 212% des valeurs temoins) . La pression arterielle moyenne a diminue d'une maniere significative avec 0,7 mg kg" 1 (48% de la valeur temoin; P<0,05). La metocurine n'a produit aucun effet hemodynamique significatif, sauf en ce qui conceme la plus forte dose (8 x ED S5 ). Les donnees obtenues laissent penser que chez le chien la marge de securite hemodynamique de la metocurine est de huit fois celle de la tubocurarine. 
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SUMARIO
Se sabe que, a raiz de sus propiedades de bloqueo ganglionico y de produccion de histamina, la tubocurarina tiene efectos hemodinamicos significativos. La metilacion del compuesto produce metocurina y deberia reducir tanto la produccion de histamina como el bloqueo ganglionico. Se compararon los efectos hemodinamicos de estos dos compuestos en 10 perros cruzados anestesiados con cloralosa y morfina. Se realizaron mediciones hemodinamicas 2 min antes y 2, 5, 10 y 20 min despues de la administration de las substancias. Cada animal recibio tres dosis de cada substancia con un periodo de descanso de 2 h entre cada dosis: 0,35 mg (contraction muscular ED 95 ), 0,7 mg y 1,4 mg kg-1 de tubocurarina y 0,2 mg (2 x ED 85 ), 0.4 mg y 0,8 mg kg-1 de metocurina. Todas las dosis de tubocurarina causaron un aumento del ritmo cardiaco (212, 197, 212% del control, respectivamente) . La presidn arterial media disminuyo de manera significativa con 0,7 mg kg-1 (48% del control P<0,05). La metocurina no tuvo ningiin efecto hemodinamico significativo, salvo en mayor dosis (8 x ED 95 ). Estos datos sugieren que el margen hemodinamico de seguridad con metocurina en el perro es ocho veces mayor que el de la tubocurarina.
